Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Details
- Employees
- 138
- Founded
- -
- Address
- 5980 Horton St,
- in****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kyvernatx.com
- Keywords
- cell therapy, autoimmune, lupus, multiple sclerosis, systemic sclerosis, scleroderma, myasthenia gravis, CAR T-cell, stiff-person syndrome.
- HQ
- Emeryville, California
Kyverna Therapeutics Questions
Kyverna Therapeutics's website is kyvernatx.com
Kyverna Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kyverna
Kyverna Therapeutics has
138 employees.
View email and phone details for 138
employees at Kyverna Therapeutics.
Kyverna Therapeutics's industry is
Biotechnology Research
Kyverna Therapeutics's top competitors are
Xaira Therapeutics,
Cargo Therapeutics,
Cabaletta Bio,
Genesis Therapeutics,
Abdera Therapeutics,
Montara Therapeutics, Inc.,
Allogene Therapeutics,
Structure Therapeutics,
Maplight Therapeutics, Inc.,
Vilya.
Kyverna Therapeutics's support email address is info@kyvernatx.com
Kyverna Therapeutics's categories are Biotechnology Research
Kyverna Therapeutics's founding year is 2018
